Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Metrics to compare | 6IV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6IVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −2.9x | −0.7x | |
PEG Ratio | 0.02 | 0.12 | 0.00 | |
Price/Book | −51.9x | 1.4x | 2.6x | |
Price / LTM Sales | 27.3x | 5.5x | 3.4x | |
Upside (Analyst Target) | - | 131.7% | 37.8% | |
Fair Value Upside | Unlock | 16.8% | 5.3% | Unlock |